Navigation Links
First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
Date:2/11/2009

ts are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether experimental pain models of pain, including the capsaicin model, are accurate in predicting efficacy of novel analgesics in early clinical trials, whether the results of any Phase II trial or other study of NGX426 will be consistent with the results of the study reported in this press release, whether TorreyPines will be able to complete any potential strategic or financing transaction on terms acceptable to TorreyPines' stockholders, how the volatile economic environment will affect TorreyPines' efforts to complete a strategic or financing transaction, whether TorreyPines' cash resources will be sufficient to fund operations as planned, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of the company's product candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of the company's product candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of the company's product candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's product development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical tri
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Max Muscle Introduces First-Ever Probiotics Protein Bar
2. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
3. Hoya Announces Third Quarter and the First Nine Months Financial Results for FY2008
4. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
5. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
6. World's First Website for Patients to Share Diagnostic-Quality Medical Images
7. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
8. BioComp Pharma Launches First Generic Drug for Tindamax(R)
9. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
10. Complete Genomics to Release Its DNA Sequencing Data for the First Time at Advances in Genome Biology and Technology Annual Meeting
11. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE MKT: ... of biosimilar therapeutics, today announced that it will be ... Marquis on March 2 nd at 3pm PST. Patrick ... a panel discussing the current state of the biosimilar ... . For more information on CALBIO ...
(Date:2/27/2015)... Feb. 27, 2015  Steep Hill, the industry leader ... internationally, intends to open a full service medical cannabis ... , bringing advanced scientific tools and methodology to ... Steep Hill is currently the only laboratory licensed by ... and contaminant testing in order to meet the recently ...
(Date:2/26/2015)... On behalf of biotech client GenScript ... Goldman & Spitzer, P.A. (Wilentz) secured a significant jury ... in excess of $10 million. The jury determined that ... that it improperly hired one or more of GenScript,s ... judgment notwithstanding the verdict, a new trial, and remittitur. ...
(Date:2/26/2015)... LEXINGTON, Mass., Feb. 26, 2015   Synageva ... a biopharmaceutical company developing therapeutic products for rare ... and provided 2015 goals, other key objectives, and ... conference call today at 4:30 p.m. EST to ... business update.  To participate in today,s call by ...
Breaking Biology Technology:Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... reporter cell lines for signal transduction pathway readout ... Alan Greener Mary Buchanan ,John Bauer Chao-Feng ... ,HLR-CREB, HLR-Elk1, and HLR-cJun, cell lines ... that converge at the transcription,factors CREB, Elk1, and c-Jun. ...
... to imitate neurodegeneration , , Rob D. Dickerman ... Walter J. McConathy a,b , a Department of ... Texas Health Science Center , , This article describes ... system cells (hNT Neurons) to imitate the,aging human brain, ...
... high-titer efficiency and larger insert,potential , ... Libraries , Katherine Felts Kim Zaharee ... Peter Vaillancourt ,Stratagene , We introduce ... inserted into the,high-titer retroviral vector pFB. ViraPort ...
Cached Biology Technology:Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion,Transactivators 2Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion,Transactivators 3Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion,Transactivators 4Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion,Transactivators 5Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion,Transactivators 6Sex Steroid Regulation of Vasopressin Levels Secreted by hNT Neurons* 2Sex Steroid Regulation of Vasopressin Levels Secreted by hNT Neurons* 3Sex Steroid Regulation of Vasopressin Levels Secreted by hNT Neurons* 4Sex Steroid Regulation of Vasopressin Levels Secreted by hNT Neurons* 5Sex Steroid Regulation of Vasopressin Levels Secreted by hNT Neurons* 6Sex Steroid Regulation of Vasopressin Levels Secreted by hNT Neurons* 7Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 2Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 3Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 4Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 5Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 6Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 7Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 8Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 9Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 10Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 11
(Date:2/19/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kx9zp8/military ) ... Electro-Optical / Infrared Systems Market by Type, by ... to 2020" report to their offering. ... expected to reach $16.35 billion by 2020, to ... report segments the military electro-optical/infrared systems market on ...
(Date:2/11/2015)... February 11, 2015 ... "Access Control Market by Product (Cards and Readers, Biometrics, ... Defense, Government, Industrial, Healthcare, Education) and By Geography - Global ... MarketsandMarkets, the Access Control Market is expected ... at a CAGR of 10.6% between 2014 ...
(Date:2/5/2015)... 26, 2015   Epic Sciences , a precision diagnostics ... that Murali Prahalad , Ph.D., president and CEO, is ... (PMWC) 2015: Silicon Valley, which is taking place at ... on January 26-28, 2015. Dr. ... as Biomarkers." Last year, Epic Sciences was a finalist in ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... A. Wells, professor and chairman of the department pharmaceutical ... director of UCSF,s small molecule discovery center, has been ... Biochemistry and Molecular Biology-Merck Award for his pioneering studies ... who also serves on the ASBMB Council, will present ...
... technological innovation with business collaboration to improve conditions for ... new Hunter and Stephanie Hunt Institute for Engineering and ... Gifts totaling $5 million from Hunter and ... B. Lyle and others will establish the institute and ...
... Scientists have designed a synthetic protein that is ... of a native protein, nitric-oxide reductase. , The ... studying nitric-oxide reductase, and for creating biocatalysts for ... Illinois chemistry professor Yi Lu, who directed the ...
Cached Biology News:University of California, San Francisco, researcher receives ASBMB-Merck Award 2New engineering institute to modify, develop technology for the global poor 2New engineering institute to modify, develop technology for the global poor 3Synthetic protein mimics structure, function of metalloprotein in nature 2
Because it is manufactured at our ISO 9001–certified facilities in Eugene, Oregon, we can guarantee that FluoroPure Grade DAPI is greater than or equal to 98% pure by HPLC....
... Smith et.al. (1997) • Contains ... current biochemistry & molecular biology, ... headwords. Entries give details of ... in which they are involved ...
... • This book describes the basic ... preparing samples for protein transfer and ... bioluminescence-enhanced detection systems are also included. ... and characterization of glycoprotein carbohydrate chains ...
... Walker (1996) • This book offers ... studying proteins and peptides. Each tried ... instruction, timesaving troubleshooting tips, alternative procedures, ... reagents and suppliers. Topics covered range ...
Biology Products: